NasdaqGM:ORKABiotechs
Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential
Oruka Therapeutics (ORKA) is back in focus after reporting Phase 2a data showing high complete skin clearance rates for psoriasis patients on ORKA-001, followed almost immediately by a US$700.35 million follow on stock offering.
See our latest analysis for Oruka Therapeutics.
At a latest share price of US$62.58, Oruka’s 1 day share price return of 8.52% and 7 day return of 9.34% follow a rapid 90 day gain of 82.45% and year to date share price return of 121.37%. The 1 year total shareholder...